MapLight director proposes $39.6K share sale
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
For MapLight Therapeutics, Inc. (MPLT), Director Robert Malenka gave notice of a proposed sale of 2,195 common shares, with an approximate sale date of February 20, 2026, and an aggregate market value of $39,576.95. Morgan Stanley Smith Barney LLC is named as broker. The shares were acquired on January 23, 2026, through restricted stock vesting under a registered plan for services. The past-three-month sales table includes a February 13, 2026, sale of 12,116 shares for gross proceeds of $220,685.67.
Key Figures
Key Terms
Restricted stock vesting under a registered plan financial
Aggregate Market Value financial
Gross Proceeds financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What prior MPLT sales by Robert Malenka are listed?
AI-generated analysis. How Rhea-AI works. Not financial advice.